The VA HDL Intervention trial (VA-HIT) was a multicenter, placebo controlled, randomized trial that showed that gemfibrozil significantly reduced major cardiovascular events in 2531 men with coronary heart disease, low levels of low density lipoprotein (LDL) cholesterol and low levels of high density lipoprotein (HDL) cholesterol. In addition to its unique lipid profile, the VA-HIT population also had a high prevalence of diabetes, impaired fasting glucose, or high fasting plasma insulin; central obesity; and hypertension, which are all components (together with high triglycerides and low ILL-cholesterol) of a constellation of risk factors known as the metabolic syndrome. Since prior clinical trials have not enrolled this type of population, the VA- HIT database is a unique resource. The purpose of the present proposal is to use this database to study additional risk markers that were measured in the study population. Specific proposed analyses are: 1. An analysis of the association between levels of glucose tolerance, insulin resistance and other features of the metabolic syndrome, occurrence of major cardiovascular outcomes, and gemfibrozil efficacy. 2. An analysis of the effect of gemfibrozil on progression of carotid atherosclerosis, as measured by B-mode ultrasound. 3. An analysis of the association between LDL particle size distribution and lipoprotein subclass distribution; homocysteine; lipoprotein(a); C- reactive protein, tissue plasminogen activator; fibrinogen; and factor VII; major cardiovascular outcomes, and gemfibrozil efficacy. Written documentation that the data will be available to us is included in the letter from Dr. Peter Peduzzi of the VA Cooperative Studies Program.
| Robins, Sander J; Collins, Dorothea; Nelson, Jeanenne J et al. (2008) Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 28:1172-8 |
| Robins, Sander J; Collins, Dorothea; McNamara, Judith R et al. (2008) Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Atherosclerosis 196:849-55 |
| Otvos, James D; Collins, Dorothea; Freedman, David S et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113:1556-63 |
